EARLY STAGE INVESTMENT


Sponsored by 



VC investment in early stage opportunities

Wednesday, September 28th (10h00-11h00)
Room A

Information

Investing in early stage opportunities is a challenge for VC managers. High needs of funds as well as long development timelines influence the high financial risk profile of such investments. How do VC investors manage those risks? Which are the tools investors can rely on for managing their early stage investment portfolios? How can closed end investment funds deal with long development timelines and likely deviations?

Moderator

Ángel Santos: Managing Director, CRB INVERBIO (Spain)

Speakers

Laia Crespo: Investment director, YSIOS CAPITAL (Spain)
Alex Casta: Investment Manager in Life Sciences, CAIXA CAPITAL RISC (Spain)
Daniela Couto: Senior Associate, BIOGENERATION VENTURES (Netherlands)
Sara Sercall: Investment Director, INVEREADY INNVIERTE BIOTECH II

 

Alternative investment in early stage opportunities

Wednesday, September 28th (11h00-12h00)
Room A

Information

Despite public perception, the financial sector does also innovate. In recent times new investor categories and vehicles have acquired a growing role in financing early stage investment opportunities, especially in IT. Nevertheless, these new categories of investors are also starting to approach the Life Sciences ecosystem. What type of alternative investors are starting to play a role in early stage investments? What type of funding can they provide?

Moderator

Shirley Kutner: Founder, BIOJERUSALEM (Israel)

Speakers

Asier Rufino: CEO, TECNALIA VENTURES (Spain)
Carla Rangel: CMO, CAPITAL CELL (Spain)
Diego Velasco: CMO, RAMON Y CAJAL HEALTH RESEARCH INSTITUTE (Spain)